How can CRISPR be used to treat Alzheimer’s disease?
DOI:
https://doi.org/10.58445/rars.1396Keywords:
CRISPR, Alzheimer'sAbstract
Alzheimer’s disease (AD) affects about 1 in 9 people above the age of 65 in the US, with projected healthcare costs reaching $1.1 trillion by 2050. Despite the severity of AD, there is no current cure, making it critical to improve current research and care. AD can be caused by a combination of genetic and environmental factors, complicating treatment efforts. However, CRISPR technology provides potential to treat the disease by manipulating certain genes involved in its pathogenesis. CRISPR treatments are currently being explored in mouse models of AD and human cells, and have the potential for improving therapeutics in human patients. The goal of this paper is to discuss how incorporating CRISPR into AD therapeutics can translate to improved care in humans.
References
Alzheimer’s Association. (2023, July 16). CRISPR/Gene Editing Technology Creates New Treatment Possibilities for Alzheimer’s Disease. AAIC 2023. Retrieved from https://aaic.alz.org/releases_2023/crispr-gene-editing-treatment-potential-alzheimers.asp#:~:text=Testing%20the%20process%20in%20an,and%20nervous%20system%20function%20deficits
Alzheimer’s Association. (2024). 2024 Alzheimer’s Disease Facts and Figures. Alzheimers Dement;20(5).
Aulston, B. D. (2023, July 16). Preclinical Research on CRISPR-Based Gene Editing for Alzheimer Disease Treatment: Brent D. Aulston, PhD. Neurology Live. https://www.neurologylive.com/view/preclinical-research-crispr-based-gene-editing-alzheimer-disease-treatment-brent-aulston
Bertram, L., & Tanzi, R. E. (2019, March 4). Alzheimer disease risk genes: 29 and counting. Nature News. https://www.nature.com/articles/s41582-019-0158-4
Johns Hopkins Medicine. (2024, June 25). Overview of nervous system disorders. https://www.hopkinsmedicine.org/health/conditions-and-diseases/overview-of-nervous-system-disorders
Karlson, C. K. S., Mohd-Noor, S. N., Nolte, N., & Tan, B. C. (2021). CRISPR/dCas9-Based Systems: Mechanisms and Applications in Plant Sciences. Plants (Basel, Switzerland), 10(10), 2055. https://doi.org/10.3390/plants10102055
Konstantinidis, E., Molisak, A., Perrin, F., Streubel-Gallasch, L., Fayad, S., Kim, D. Y., Petri, K., Aryee, M. J., Aguilar, X., György, B., Giedraitis, V., Joung, J. K., Pattanayak, V., Essand, M., Erlandsson, A., Berezovska, O., & Ingelsson, M. (2022). CRISPR-Cas9 treatment partially restores amyloid-β 42/40 in human fibroblasts with the Alzheimer's disease PSEN1 M146L mutation. Molecular therapy. Nucleic acids, 28, 450–461. https://doi.org/10.1016/j.omtn.2022.03.022
Lanoiselée, H. M., Nicolas, G., Wallon, D., Rovelet-Lecrux, A., Lacour, M., Rousseau, S., Richard, A. C., Pasquier, F., Rollin-Sillaire, A., Martinaud, O., Quillard-Muraine, M., de la Sayette, V., Boutoleau-Bretonniere, C., Etcharry-Bouyx, F., Chauviré, V., Sarazin, M., le Ber, I., Epelbaum, S., Jonveaux, T., Rouaud, O., … collaborators of the CNR-MAJ project (2017). APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases. PLoS medicine, 14(3), e1002270. https://doi.org/10.1371/journal.pmed.1002270
Mayeux, R., & Stern, Y. (2012). Epidemiology of Alzheimer disease. Cold Spring Harbor perspectives in medicine, 2(8), a006239. https://doi.org/10.1101/cshperspect.a006239
Mayo Foundation for Medical Education and Research. (2023, April 29). The role of genes in your Alzheimer's risk. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/in-depth/alzheimers-genes/art-20046552#:~:text=The%20most%20common%20type%20of,APOE%20e2
National Institute on Aging. (2022, October 18). What are the signs of Alzheimer's disease? | National Institutes of Health. https://www.nia.nih.gov/health/alzheimers-symptoms-and-diagnosis/what-are-signs-alzheimers-disease#:~:text=For%20most%20people%20with%20Alzheimer%E2%80%99s,30s,%20although%20this%20is%20rare
National Institute on Aging. (2023, March 1). Alzheimer’s disease genetics fact sheet | National Institute on Aging. https://www.nia.nih.gov/health/alzheimers-causes-and-risk-factors/alzheimers-disease-genetics-fact-sheet
National Institute on Aging. (2024, January 19). What happens to the brain in Alzheimer's disease? | National Institute on Aging. https://www.nia.nih.gov/health/alzheimers-causes-and-risk-factors/what-happens-brain-alzheimers-disease
NHS. (2024, July 4). Diagnosis -Alzheimer’s disease. NHS choices. https://www.nhs.uk/conditions/alzheimers-disease/diagnosis/#:~:text=There%27s%20no%20simple%20and%20reliable,about%20your%20memory%20or%20thinking
Ortiz-Virumbrales, M., Moreno, C. L., Kruglikov, I., Marazuela, P., Sproul, A., Jacob, S., Zimmer, M., Paull, D., Zhang, B., Schadt, E. E., Ehrlich, M. E., Tanzi, R. E., Arancio, O., Noggle, S., & Gandy, S. (2017). CRISPR/Cas9-Correctable mutation-related molecular and physiological phenotypes in iPSC-derived Alzheimer's PSEN2 N141I neurons. Acta neuropathological communications, 5(1), 77. https://doi.org/10.1186/s40478-017-0475-z
Osmosis from Elsevier. (2016, March 22). "Alzheimer’s disease - plaques, tangles, causes, symptoms & pathology". YouTube. https://www.youtube.com/watch?v=v5gdH_Hydes
Practical Neurology. (2023, July 17). CRISPR/dcas9 shows promise in editing Apoe Ε4 to treat late onset alzheimer disease. Practical Neurology. https://practicalneurology.com/news/crisprdcas9-shows-promise-in-editing-apoe-e4-to-treat-late-onset-alzheimer-disease
Roberts, R. (2024, June 21). CRISPR Clinical Trials to Follow in 2024 and Beyond. Synthego. https://www.synthego.com/blog/crispr-clinical-trials-2024#:~:text=Genetic%20disorders%20are%20still%20one,disorders%2C%20and%20other%20rare%20disorders
Robertson, S. (2023, January 2). What are amyloid plaques?. News Medical Life Sciences . https://www.news-medical.net/health/What-are-Amyloid-Plaques.aspx#:~:text=Amyloid%20plaques%20are%20aggregates%20of,memory%20and%20other%20cognitive%20functions
Stefanacci R. G. (2011). The costs of Alzheimer's disease and the value of effective therapies. The American journal of managed care, 17 Suppl 13, S356–S362.
Synthego. (n.d.). What Is CRISPR: The Ultimate Guide To CRISPR Mechanisms, Applications, Methods & More. https://www.synthego.com/learn/crispr
Thorne, L. (2024, January 11). CRISPR gene therapies: Current challenges and a promising future. https://www.biocompare.com/Editorial-Articles/609559-CRISPR-Gene-Therapies-Current-Challenges-and-a-Promising-Future/
Wang, C., Najm, R., Xu, Q., Jeong, D. E., Walker, D., Balestra, M. E., Yoon, S. Y., Yuan, H., Li, G., Miller, Z. A., Miller, B. L., Malloy, M. J., & Huang, Y. (2018). Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector. Nature medicine, 24(5), 647–657. https://doi.org/10.1038/s41591-018-0004-z
Xu, Y., & Li, Z. (2020). CRISPR-Cas systems: Overview, innovations and applications in human disease research and gene therapy. Computational and structural biotechnology journal, 18, 2401–2415. https://doi.org/10.1016/j.csbj.2020.08.03
Downloads
Posted
Versions
- 2024-09-12 (2)
- 2024-08-04 (1)
Categories
License
Copyright (c) 2024 Roya Bahman
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.